Abstract: A potent, small molecule inhibitor with a favorable pharmacokinetic profile to allow for sustained SCD inhibition in vivo was identified. Starting from a low MW acyl guanidine (5a), identified with a RapidFire HighThroughput Mass Spectrometry (RF-MS) assay, iterative library design was used to rapidly probe the amide and tail regions of the molecule. Singleton synthesis was used to probe core changes. Biological evaluation of a SCD inhibitor (5b) included in vitro potency at SCD-1 and in vivo modulation of the plasma desaturation index (DI) in rats on a low essential fatty acid (LEFA) diet. In addition to dose-dependent decrease in DI, effects on rodent ocular tissue were noted. Therefore, in rat, these SCD inhibitors only recapitulate a portion of phenotype exhibited by the SCD-1 knockout mouse. The sirtuin enzymes, a class of NAD+-dependent histone deacetylases, are a focal point of epigenetic research because of their roles in regulating gene expression and cellular differentiation by deacetylating histones and a host of transcription factors, including p53. Here, the authors present two label-free screening methodologies to study sirtuin activity using high-throughput mass spectrometry. The first method involves the detection of native peptides and provides a platform for more detailed mechanistic studies by enabling the concurrent and direct measurement of multiple modification states. The second method obviates the need for substrate-specific assay development by measuring the O-acetyl-ADP-ribose co-product formed by sirtuin-dependent deacetylation. Both methodologies were applied to investigating the deacetylation of multiple-peptide substrates by multiple-sirtuin enzymes. Kinetic data, including binding constants, inhibition, and, in some cases, activation, are demonstrated to correlate well, both between the methodologies and with previous literature precedent. In addition, the ability to monitor sirtuin activity via Oacetyl-ADP-ribose production permits experimentation on whole-protein substrates. The deacetylation of wholehistone proteins by SIRT3, and inhibition thereof, is presented and demonstrates the feasibility of screening sirtuins using more biologically relevant molecules.
possible acetylation states of a peptide concurrently to measure HAT activity. The second approach measures acetylation reactions, on both peptides and whole protein substrates, via direct detection of the acetyl-coenzyme A cosubstrate and coenzyme A coproduct. Lastly, the authors demonstrate the ability to monitor directly the acetylation state of whole histone proteins in the same high-throughput manner using time-of-flight mass spectrometry. The generation of compound-mediated inhibition data using each of these techniques establishes mass spectrometry as a versatile, label-free, and biologically relevant screening approach to this challenging target class.
Label-free high-throughput screening via mass spectrometry: a single cystathionine quantitative method for multiple applications.
Abstract: Mass spectrometry-based screening can be applied to a wide range of targets, including those intractable targets that use substrates such as lipids, fatty acids, phospholipids, steroids, prostaglandins, and other compounds not generally amenable to conventional screening techniques.The major limitation to this approach is throughput, making HTS via mass spectrometry impractical.We present a mass spectrometry-based technique and hardware for lead discovery applications. Massspectrometry enables the design of label-free assays using biologically native substrates for a widerange of enzymatic targets. This system can be used for the direct quantification of analytes incomplex reaction mixtures with typical throughputs of 4Ð5 s per sample. A mass spectrometrybasedassay was developed to identify inhibitors of acetylcholinesterase, an enzyme with clinicalimportance in AlzheimerÕs disease. The system was used to screen a small chemical library. Severalpotent inhibitors were identified, and the IC50 values of the inhibitors were determined. 
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SBS -BIOCIUS (poster) Advances in Label-Free Screening Approaches for Studying Histone Acetyltransferases
Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from an acetyl-coenzyme A donor molecule to sequence specific lysine residues within proteins The acetylation state of proteins particularly histones is known to modulate their intermolecular binding properties and control various cellular processes, most notably transcriptional activation. Additionally, deregulation of HAT activity has been linked to the development of a number of cancers; therefore, compounds that affect these enzymes have strong potential as therapeutic agents. The research presented here demonstrates three label free HAT screening approaches all based upon the fast and direct measurement of one or more substrate/product pairs by high-throughput mass spectrometry techniques. One approach involves monitoring all possible acetylation states of a peptide concurrently to measure HAT activity. Another approach measures cosubstrate and coenzyme A coproduct. Lastly, we demonstrate the ability to monitor directly the acetylation state of whole histone proteins in the same high-throughput manner using time-of-flight (TOF) mass spectrometry. The generation of compound-mediated inhibition data using each of these techniques establishes mass spectrometry as a versatile labelfree and biologically-relevant screening approach to this challenging target class.
ASMS --Bristol-Myers Squibb (poster)
Development of a High-Throughput MS-Based Bioanalytical Method for Assessment of PGlycoprotein Inhibition
Evaluation of drug-drug interactions between potential drug candidates and transporters such as P-glycoprotein (P-gp) is an integral part of early liability screening in drug discovery. Inhibition of P-gp can be determined by performing bidirectional Caco-2 permeability studies with digoxin as a substrate probe. Existing methodologies include either assaying H3-digoxin with liquid scintillation counting or assaying non-labeled digoxin with LC-MS detection at a speed of several minutes per sample. Our goal was to develop an analytical method that was "label-free" and provided ample throughput to support this potentially high-volume assay. Mass spectrometric detection was the ideal choice for digoxin analysis because it is "label-free", sensitive, specific, and reliable. However, it is not possible to achieve a bioanalytical throughput high enough to support a screening assay using traditional LC-MS/MS. To address this, we developed an ultra-fast method for digoxin analysis on the BIOCIUS RapidFire™ (RF)-MS/MS system with a cycle time of ~9 seconds per sample. In order to validate the accuracy of the RFMS/ MS method, a traditional LC-MS/MS method was established for results comparison. Data processing was made feasible through the development of inhouse macros that utilize XLfit for standard curve linear regression and calculation of preliminary results. The resulting data suggests that the RF-MS/MS method generates equivalent results to both LC-MS/MS and radiolabel assays in determining inhibitors of P-glycoprotein.
Evaluation of Accurate Mass TOF-MS for Use in High Throughput PAMPA & Plasma Protein Binding Screens
Assays that measure permeability (i.e. PAMPA) and plasma protein binding (PPB) are used to screen drug compounds early in the discovery process to eliminate poor performers and/or to identify compounds that need to be modified. Mass spectrometry has emerged as the preferred analysis method for these assays due to its sensitivity, specificity, and robustness. Traditionally, these assays utilize tandem MS, which is limited by its requirement for compound dependent method development. The use of accurate mass offered by time of flight (TOF) mass spectrometers, which eliminates the need for MRM optimization, was investigated here and has implications for a wide range of other in vitro ADME assays where MS method development is a bottleneck.
A diverse set of commercially available drug compounds with a broad spectrum of physical chemical properties were assayed. Samples were analyzed at a rate of 6-8 seconds per sample using an ultrafast SPE-MS system consisting of a RapidFire RF300 interfaced to an ABSciex API4000 or a RapidFire RF360 interfaced to an Agilent 6530 Q-TOF. MS conditions for each compound were optimized on the QqQ while generic MS conditions were used for all compounds on the Q-TOF. A single generic SPE condition was used for all analyzes.
For each assay, the results using the SPE-TOF were comparable to literature values and correlated very well with results from the SPE-MS/MS system (R2> 0.9). Interestingly, the Q-TOF successfully analyzed compounds that could not be analyzed on the QqQ. The tight correlation in assay values determined on the two different instruments suggests that the use of exact mass MS instrumentation is a valid alternative to MRM method development for the analysis of PAMPA & plasma protein binding assays. Eliminating MRM method development significantly streamlined workflow and improved laboratory efficiency. These generic SPE-TOF methods may also be useful for other in vitro ADME assays that typically utilize QqQ analysis.
ASMS --GSK (poster)
Label-free High-throughput Whole Protein Kinase Screening Assay
Protein kinases are involved in the regulation of multiple cellular processes by catalyzing phosphorylation of target substrates. Dysregulation of kinase activity has been found in a variety of diseases; therefore, protein kinase inhibitors offer an opportunity to target these diseases. To facilitate the screening and characterization of kinase inhibitors, we developed a mass spec-based high throughput screening method to measure their effect on kinase activity, permitting the use of whole protein substrates which advantageously allows detection of both competitive and non-competitive inhibitors. In addition, this assay does not rely on site-specific antibodies, allowing detection of phosphorylated serine, threonine, or tyrosine residues. Lastly, mass spectrometry facilitates quantitative interrogation of complex kinetics in proteins with multiple phosphorylation sites.
ASMS --OSI (poster)
Discovery of Novel Inhibitors of Serine Palmitoyltransferase (SPT) by Mass Spectrometrybased High-throughput Screening (HTS)
Obesity has been linked with increased ceramide accumulation and resultant impaired insulin sensitivity. SPT may represent an attractive enzyme to target within the ceramide synthetic pathway in order to treat type 2 diabetes. A mass spectrometry based HTS approach to identify inhibitors of mammalian SPT was used to screen a library of >250,000 small molecules. Screening identified potent SPT inhibitors from multiple chemotypes. A mass spectrometry-based HTS approach was developed to identify inhibitors of SPT, an enzyme that was previously intractable to conventional screening methods. The screen successfully identified potent inhibitors of mammalian SPT activity across several distinct chemotypes.
ASMS 2009 --Merck (User Symposium Presentation) "The Application of RapidFire MS in a High-throughput Production Assay Lab"
This presentation, authored by Merck Research Labs: Deborah Zink, Tom Holt, Jonathon Lum, Marta Arocho, Anne Vergnon, Gerica Galviz, Claude Dufresne, deals with Merck's initially outsourced RapidFire project to develop production assays for drug-drug interaction. They state that they went from zero to five production assays in less than 5 months and, ultimately, brought the instrument in-house. They further describe they successfully tested overnight operation of the instrument and that they expected payback on purchase cost in 5 months.
ASMS 2009 --Boehringer-Ingelheim (User Symposium Presentation) "A Novel and Integrated Platform for Fully Automated High Throughput LC-MS/MS Analysis of in vitro ADME Sample"
This presentation, authored by Andreas H. Luippold -Boehringer Ingelheim Pharma GmbH & Co KG , describes how BI reduced cycle times from 80 minutes to 13 minutes for a 96 well plate using RapidFire technology.
SBS --Genzyme (poster) Discovery of Small Molecule Inhibitors of GM3 Synthase via High-throughput Mass Spectroscopy
A label-free biochemical HTS assay using the RapidFire system was developed and HTS was performed to find small molecule inhibitors of GM3 synthase. A collection of 250,000 compounds were screened at 10 uM in singlicate. 1816 hits have been identified which resulted in a hit rate of 0.7 %, 1217 hits were confirmed in duplicate at 10 uM, resulting in a confirmation rate of 67%. Currently confirmed hits are under evaluation for potency and selectivity. Confirmed potent and specific hits for GM3 synthase from the biochemical screen will help to guide medicinal chemistry efforts to find a small molecule inhibitor of GM3 synthase. RapidFire system enables measurement of enzymatic activity of proteins which are difficult to measure by other known conventional methods. We have shown that RapidFire system can be used for multiple enzyme assays such as GM3 Synthase and ST6Gal-1.
SBS -BIOCIUS (poster)
High-throughput Mass Spectrometric Detection of Histone 3 Demethylation
Here we illustrate the utility of RapidFire-MS to study epigenetic changes directly, using reactions between LSD1 enzyme and a dimethylated Histone3 peptide (H3K4me2) as an example. The RapidFire platform enables highthroughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HLPC, which requires minutes.
Early Phase Identification of Candidates for Epigenetic Drug Targets
The Situation: A biopharmaceutical company focused on the emerging field of epigenetic-based drug targets sought a faster, more efficient way to advance their screening programs. Traditionally, epigenetic targets were screened using conventional screening methods; however, this company was interested in a native analyte-based technology that could provide more biologically relevant data from assays measuring slight modifications in protein structure.
Addressing the Challenges: Working with BIOCIUS in-house scientists, assays for methylases, acetylases, phosphorylases and other modifying enzymes involved in histone and chromatin modulation were developed and optimized. The RapidFire mass spec platform had the ability to investigate reactions that are not practical using HPLC, fluorescence, or luminescence screening methodologies. The technology avoids some confounding effects (such as auto-fluorescence) and provides fast, high capacity sample analysis throughput that is required in early drug discovery.
Results: With the RapidFire system, the client was able to use biologically relevant assays earlier in the discovery process, ultimately providing rapid and accurate data analysis, reducing R&D time, and enabling faster identification of promising new lead compounds for epigenetic drug development.
ELRIG -BIOCIUS (poster)
Consistent, High-throughput Metabolic Stability Screening Across Mass Spectrometry Platforms
The metabolic half-life or stability of a drug candidate has important pharmacokinetic and clinical significance in vivo, because it influences both oral bioavailability and plasma concentration of a compound, which in turn, affect its efficacy. Therefore, a high-throughput metabolic stability assay is a valuable tool in the go/no-go decision-making process in drug discovery. However, conventional LC-MS requires several minutes per sample processing time. Using the RapidFire system, we have developed analytical techniques which lower analysis times to only a few seconds per sample, allowing metabolic stability assays to be performed at throughputs consistent with other drug discovery screening platforms. In the present study we evaluated the compatibility of the RapidFire system with 3 MS platforms (ABI/Sciex, ThermoFisher, and Agilent) by measuring half lives using conventional assay methods. The values measured across all MS platforms tested were within a 2-fold window. This data shows that the RapidFire system produces consistent, high-throughput, metabolic stability data across multiple MS platforms enabling performance of these critical assays in a typical drug discovery environment.
Protein Society -Amgen/BioTrove (poster) Screening for ATP Citrate Lyase Inhibitors Using Mass Spectrometry
Used RapidFire to identify potential ACL inhibitors, screened more than 43,600 compounds in single point and more than 300 IC50 follow-ups. Showed that the RapidFire platform is ideal for identifying and verifying lead compounds such as Compound A and Compound B. RapidFire technology was also used to look at SAR around these most potent compounds as well as investigate reversibility and probe the mechanisms of inhibition. Using both RapidFire and FT-Orbitrap® mass spectrometry to characterize PKA treated ACL researchers phosphoresidue mapped and assayed under Vmax conditions, though report only marginally lower activity with the unphosphorylated ACL enzyme as opposed to Potapova et.al. who report a 6-fold increase in ACL phosphorylated by PKA. In addition, the high resolution of FT-Orbitrap enabled the direct analysis of ACL activity in cells and demonstrates compensatory increase in cellular AcetylCoA levels upon inhibition.
SBS --Pfizer (poster) The Use of High Throughput Mass Spectrometry (HTMS) in Drug Discovery
The 1st generation of RapidFire instrument was delivered to Pfizer Groton HTS Center of Emphasis (CoE) in Sept. 2006. In 2007, the HTS CoE has applied the HTMS system to: Assay development and Subset screening for DGAT; Hit to Lead exploration with Stearoyl CoA Desaturase (SCD); Assay Development for SirT1. In 2008, we have expanded our impact by supporting 7 drug targets at various discovery stages.
SBS --Merck (poster) Identification of Inhibitors for the Phosphatidylethanolamine N-methytransferase Enzyme by High-Throughput Mass Spectrometry Detection of Reaction Products
Phosphatidylethanolamine N-methyltransferase (PEMT) is the enzyme that transfers methyl groups from SAM to phosphatidylethanolamine (PE), to generate phosphatidylcholine (PC) and SAH. It has been reported that in PEMT -/-mice there is a decrease in plasma PC and cholesterol found in high density lipoproteins when compared to wild type mice. Thus it might be of interest to see how PEMT inhibitors could modulate the levels of plasma lipoproteins. Two inhibitors were identified, with potency equivalent or higher than SAH, and could represent interesting lead molecules for the development of potent and selective inhibitors of PEMT. Such compounds could be used in a relevant animal model of atherosclerosis to evaluate the role of PEMT in this disease
SBS --Bayer (poster)
High-Throughput Mass Spectrometry Screening for Inhibitors of Phosphatidylserine Decarboxylase
Abstract: A high-throughput mass spectrometry assay to measure the catalytic activity of phosphatidylserine decarboxylase (PISD) is described. PISD converts phosphatidylserine (PS) to phosphatidylethanolamine (PE) during lipid synthesis. Traditional methods of measuring PISD activity are low throughput and unsuitable for the highthroughput screening of large compound libraries. The high throughput mass spectrometry assay measures phosphatidylserine and phosphatidylethanolamine directly using the RapidFire platform at a rate of one sample every 7.5 s. The assay is robust, with an average Z′ value of 0.79 from a screen of 9,920 compounds. Of 60 compounds selected for confirmation, 54 are active in doseresponse studies. The application of high-throughput mass spectrometry permitted a high-quality screen to be performed for an otherwise intractable target Abstract: The Cytochrome P450 (CYP) enzymes are involved in many drug metabolism transformations and account for a significant number of bioactivation and metabolic reactions. The presence of some drugs can interfere with the metabolic activity of CYP enzymes causing drug-drug interactions. Analysis of potential drug-drug interactions caused by inhibition of the enzymatic activities of CYP enzymes plays an important role in the drug discovery process. The ever increasing need to evaluate a large number of samples and the need to eliminate weaker candidates in the initial phase of the drug discovery process, has created a bottleneck at LC/MS/MS analysis. We evaluated the use of an ultrafast online SPE/MS system (the Agilent RapidFire High-throughput Mass Spectrometry system) coupled to an Agilent QqQ and Agilent QTOF for the analysis of pooled samples across several CYP450 isoforms in a single cassette injection mode to provide an even faster and more cost-effective screen.
AAPS -BIOCIUS (poster)
Streamlining ADME Workflow Using SPE-TOF Analysis
The throughput of in vitro ADME analysis is gaining an almost equal footing with data quality as a determinant of laboratory workflow. These assays have traditionally utilized tandem MS, which is limited by its requisite MRM method development that requires several minutes per sample of processing time.
The use of accurate mass offered by high resolution (time of flight: TOF) mass spectrometers, which eliminates the need for MRM optimization, in conjunction with a high throughput solid phase extraction (SPE) system was investigated to assess its ability to enable a faster and more efficient assay analysis workflow.
We compared the assay results for a panel of in vitro ADME assays (CYP inhibition, metabolic stability, PAMPA and plasma protein binding) using ultrafast SPE-MS/MS and SPE-TOF systems for analysis. A chemically diverse set of 50 compounds was used for each assay and all analyses utilized the same generic SPE conditions. All SPE-TOF analyses were performed using the same generic MS conditions with a RapidFire 360 interfaced to an Agilent 6530 Q-TOF run in ESI-TOF mode. The experimental results obtained for all four of the ADME assays by each analysis system were comparable (R2 >0.9).
Using a generic SPE condition, the ultrafast SPE-MS systems consistently produced sample analysis cycle times of 7 seconds/sample with no changes to standard laboratory workflow and no significant sample carryover. Using a generic MS method, the TOF analysis gave comparable results to conventional triple quadruple analysis. Assay results with the SPE-TOF system were comparable to the SPE-MS/MS system for a variety of ADME assays indicating that MRM method development could be eliminated for these assays providing a significant increase in efficiency of laboratory workflow. The SPE-TOF system enabled faster and more efficient assay data analysis across a panel of ADME assays without compromising the quality of results.
AAPS --Novartis (poster)
Ultra-fast Solubility Sample Analysis Using SPE-MS/MS
We investigated the utility of solid phase extraction (SPE) coupled with mass spectrometry for improving sample throughput of the solubility assay. The current method for solubility sample analysis employs HPLC with ultraviolet absorbance detection (UV). We investigated a SPE-TOF system consisting of an ultra-fast SPE system (RapidFire®) linked to an Agilent 6530 Q-TOF mass spectrometer. The two analytical methods were compared using a set of compounds from Novartis' drug discovery programs that covered a wide range of chemical space and properties. Solubility was measured in triplicate in pH 6.8 buffer and in FASSIF buffer. A four point calibration curve was prepared to quantify the solubility of each sample. The SPE-TOF method had a cycle time of eight seconds compared to two minutes for the HPLC-UV method. This represents a 15-fold improvement in cycle time, which can be used to increase the capacity of this assay. The SPE-TOF method was able to maintain data quality as evidenced by linear standard curves (r2 ≈ 0.99) and back-calculated standards within 30%. Moreover, a correlation plot of the solubility determined using SPE-TOF vs. HPLC/UV was linear with a slope of approximately one and an r2 > 0.8. 
APA -J&J/BIOCIUS (poster)
